IDH2 and acute myeloid leukemia: Enasidenib is currently being evaluated in combination regimens with agents such as azacitidine or induction chemotherapy in patients with newly diagnosed IDH2-mutated AML (Agios Pharmaceuticals, Inc., 2017).